200 related articles for article (PubMed ID: 17404074)
1. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
Massarweh S; Schiff R
Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
[TBL] [Abstract][Full Text] [Related]
2. Overcoming Endocrine Resistance in Breast Cancer.
Hanker AB; Sudhan DR; Arteaga CL
Cancer Cell; 2020 Apr; 37(4):496-513. PubMed ID: 32289273
[TBL] [Abstract][Full Text] [Related]
3. Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities.
Yan S; Ji J; Zhang Z; Imam M; Chen H; Zhang D; Wang J
Biomed Pharmacother; 2024 Jun; 175():116615. PubMed ID: 38663101
[TBL] [Abstract][Full Text] [Related]
4. Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.
Smart E; Semina SE; Frasor J
Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32887995
[TBL] [Abstract][Full Text] [Related]
5. Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers.
Truong TH; Lange CA
Endocrinology; 2018 Dec; 159(12):3897-3907. PubMed ID: 30307542
[TBL] [Abstract][Full Text] [Related]
6. Targeting systemic and gut microbial metabolism in ER
Heath H; Mogol AN; Santaliz Casiano A; Zuo Q; Madak-Erdogan Z
Trends Endocrinol Metab; 2024 Apr; 35(4):321-330. PubMed ID: 38220576
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
Arpino G; Wiechmann L; Osborne CK; Schiff R
Endocr Rev; 2008 Apr; 29(2):217-33. PubMed ID: 18216219
[TBL] [Abstract][Full Text] [Related]
8. Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs.
Ke CH; Lin CN; Lin CS
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255807
[TBL] [Abstract][Full Text] [Related]
9. Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome.
Elnaghi KAEA; Alghanmi HA; Elsamany SA; Almarzoki F; Elsafty M; Jaffal M
Breast J; 2023; 2023():8994954. PubMed ID: 37664544
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of Anticancer Drugs: Clinical Response and Toxicity.
Siddique A; Bashir S; Abbas M
Cancer Treat Res; 2023; 185():141-175. PubMed ID: 37306909
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients.
Radziuviene G; Rasmusson A; Augulis R; Grineviciute RB; Zilenaite D; Laurinaviciene A; Ostapenko V; Laurinavicius A
Front Oncol; 2021; 11():774088. PubMed ID: 34858854
[TBL] [Abstract][Full Text] [Related]
12. AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
Martorana F; Motta G; Pavone G; Motta L; Stella S; Vitale SR; Manzella L; Vigneri P
Front Pharmacol; 2021; 12():662232. PubMed ID: 33995085
[TBL] [Abstract][Full Text] [Related]
13. Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer.
Tahiri A; Tekpli X; Satheesh SV; DeWijn R; Lüders T; Bukholm IR; Hurtado A; Geisler J; Kristensen VN
Breast Cancer Res Treat; 2020 Oct; 183(3):585-598. PubMed ID: 32710281
[TBL] [Abstract][Full Text] [Related]
14. Expression and localization of estrogen receptors in human renal cell carcinoma and their clinical significance.
El-Deek HEM; Ahmed AM; Hassan TS; Morsy AM
Int J Clin Exp Pathol; 2018; 11(6):3176-3185. PubMed ID: 31938447
[TBL] [Abstract][Full Text] [Related]
15. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
[TBL] [Abstract][Full Text] [Related]
16. Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer.
Sareyeldin RM; Gupta I; Al-Hashimi I; Al-Thawadi HA; Al Farsi HF; Vranic S; Al Moustafa AE
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31083383
[TBL] [Abstract][Full Text] [Related]
17. Disrupting a negative feedback loop drives endocrine therapy-resistant breast cancer.
Foulds CE
Proc Natl Acad Sci U S A; 2018 Aug; 115(33):8236-8238. PubMed ID: 30082387
[No Abstract] [Full Text] [Related]
18. Crosstalk between ERα and Receptor Tyrosine Kinase Signalling and Implications for the Development of Anti-Endocrine Resistance.
Montaser RZ; Coley HM
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29925812
[TBL] [Abstract][Full Text] [Related]
19. Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets.
Gates LA; Gu G; Chen Y; Rohira AD; Lei JT; Hamilton RA; Yu Y; Lonard DM; Wang J; Wang SP; Edwards DG; Lavere PF; Shao J; Yi P; Jain A; Jung SY; Malovannaya A; Li S; Shao J; Roeder RG; Ellis MJ; Qin J; Fuqua SAW; O'Malley BW; Foulds CE
Oncogene; 2018 Aug; 37(33):4581-4598. PubMed ID: 29748621
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
